Navigation Links
Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
Date:5/13/2009

RICHMOND, Calif., May 13 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 10:00 am PT on Wednesday, May 20, 2009 at the Eighth Annual JMP Securities Conference which will be held in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
3. Sangamo BioSciences Reports First Quarter 2009 Financial Results
4. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
5. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
6. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
7. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
8. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
9. Anaptys Biosciences Raises Over $33 Million in Series B Financing
10. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
11. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/13/2010)... -- The American Association of Public Health Physicians submitted a petition to the ... their official stance concerning electronic cigarettes . They cite many concerns, including ... have in the future. , ... ... , ...
(Date:3/13/2010)... Reflex Nutrition is proud to announce a new variety of their ... is called Instant Whey Deluxe and has been specifically designed to ... ... (PRWEB) March 13, 2010 -- Traditionally Reflex Nutrition has always ... immensely popular Instant Whey contains an industry high protein ...
(Date:3/13/2010)... The Zone, leads the 11th annual Zone Cruise to beautiful Caribbean ... new Zone foods prepared according to standard Zone recipes. , ... ... sail to better health, devotees of the globally popular Zone ... Dr. Barry Sears, Zone diet creator and best selling author of ...
(Date:3/13/2010)... ORLEANS, LA A new minimally invasive sports ... times faster than the traditional repair, according to a ... for Sports Medicine,s Specialty Day in New Orleans, (March ... prior to this new repair had a lengthy rehabilitation ... Tom Brady, Philadelphia Eagles Donovan McNabb and Kevin Curtis, ...
(Date:3/13/2010)... today at the American Orthopaedic Society for Sports Medicine,s ... that 95 percent of skeletally mature high school pitchers ... Almost as many, (94.7 percent) returned to competitive baseball. ... a damaged elbow ligament (ulnar collateral ligament or UCL) ... body. The surgery is named for Hall of Fame ...
Breaking Medicine News(10 mins):Health News:Electronic Cigarettes Are Tobacco Products, States AAPHP 2Health News:Electronic Cigarettes Are Tobacco Products, States AAPHP 3Health News:Electronic Cigarettes Are Tobacco Products, States AAPHP 4Health News:Whey Protein Pioneers Announce The World's Best Tasting Protein Powder 2Health News:Zone Diet Devotees Set Sail with Dr. Barry Sears on Zone Cruise to Better Health 2Health News:Minimally invasive sports hernia repair may get athletes 'back in the game' faster, study says 2Health News:'Tommy John' elbow reconstruction 95 percent successful with grown teen pitchers, study says 2
... yesterday that they were investigating eight suspected bird flu cases ... of these cases had been fatal. ,A team ... this stage we can say they are still suspect at ... Kandun, head of the Health Ministry's office of communicable disease ...
... and followed that patients on medications for blood pressure ... soon.,Those affected can now safely consume grapefruit juice- which ... on this juice for some was due to some ... overdoses and dangerous side effects. ,The answer has been ...
... developing countries of the Asia Pacific region, Pakistan is ... two out of three Pakistanis are illiterate. // ... Education's findings contradicts claims that the Education Sector Reforms ... country. ,Confirming the report's findings, an education ...
... coffee cafes, on opening its 300th outlet in Mumbai on Wednesday ... by the year 2007. // ,"It has been ... a large role in firmly establishing the coffee café culture in ... Trading Company Ltd., the parent company of the chain. ...
... survey that found that almost 80 percent of Shanghai women ... ,Yu Junde, coordinator of Survey and head official of Shanghai ... wearing of bras which could affect their health. ... 18 to 50, which revealed that many were wearing very ...
... the survival rates has been documented in Acute Coronary ... analysis reported at the Society for Cardiovascular Angiography and ... May 10–13. ,By combining data from nine ... than in combination, the analysis was able to put ...
Other Medicine News:Health News:Shanghai Women Don their Bras Improperly 2Health News:Statin Therapy in Patients with Acute Coronary Syndrome Improves Survival 2
(Date:3/12/2010)... -- Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey , Chairman and CEO: ... licensing agreement with the Johns Hopkins University ,s Brain Science Institute (Headquarters: ... Eisai,s GCPII (glutamate carboxypeptidase II) technology.   , ... ... ...
(Date:3/12/2010)... today announced financial results for the fourth quarter and year ended December 31, 2009 .   , ... , ... ... ... Novavax reported a net loss of $14 million , or $0.15 per share, for the fourth quarter of 2009 compared to ...
(Date:3/12/2010)... Taiwan , March 12 ... today the Phase II trial of ... with once-a-day dosing met the primary ... good tolerability. Nemonoxacin is a,novel non-fluorinated ... of activity against,gram-positive and gram-negative bacteria ...
Breaking Medicine Technology:Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 2Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 3NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results 2NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results 3NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results 4NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results 5NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results 6NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results 7NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results 8NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results 9NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results 10TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints 2TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints 3Genedata and the Institute of Experimental Medicine Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 14522 1Genedata and the Institute of Experimental Medicine Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 14522 2Genedata and the Institute of Experimental Medicine Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 14522 3Genedata and the Institute of Experimental Medicine Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 14522 4Hangovers May Be Tougher for Migraine Sufferers 59737 1Drugs for Irritable Bowel Might Increase Cancer Risk 59736 1Drugs for Irritable Bowel Might Increase Cancer Risk 59736 2
... the 42nd annual meeting of the European,Association for ... April 11, 2007 /PRNewswire-FirstCall/ --,Schering-Plough Corporation reaffirms its ... hepatitis C virus (HCV),infection with several key data ... the Liver (EASL) 42nd annual meeting,in Barcelona, Spain, ...
... - INNOVIVE Pharmaceuticals,Inc. (OTCBB:IVPH) today announced that ... INNO-406, an orally bioavailable dual Bcr-Abl and,Lyn-kinase ... will be presented at the American,Association for ... INNO-206, a doxorubicin prodrug for the,treatment of ...
Other Medicine Technology:Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 2Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 3Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 4Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 5Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 6Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 7Innovive Pharmaceuticals Announces Data from Oncology Drug Programs,to be Presented at American Association for Cancer Research Annual,Meeting 2Innovive Pharmaceuticals Announces Data from Oncology Drug Programs,to be Presented at American Association for Cancer Research Annual,Meeting 3
... Expandable Tip System A lower cost alternative ... to perform multi-sample transfers between two different vessel ... knob, tip spacing can be quickly and easily ... 96 well plates. Ergonomic Design for Unparalleled ...
... 384 Well Plate Capability The Equalizer ... original Equalizerexpandable and equal tip spacing, choice of ... capabilities. In addition, this model allows you to ... loading and accessing many gels and for use ...
... System A lower cost alternative to Equalizers, ... multi-sample transfers between two different vessel configurations. With ... spacing can be quickly and easily adjusted for ... plates. Ergonomic Design for Unparalleled Comfort ...
Packaging: Set includes: Eight-channel pipette (10.8 mm with 0.5-5.0 μl capacity) 25 PrismStrip 96 tips with rack 2 FlexPlates with a holder...
Medicine Products: